Âé¶¹´«Ã½Ó³»­

Âé¶¹´«Ã½Ó³»­

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Scapuloperoneal Myopathy and Cardiomyopathy with a Novel MYH7 Mutation: A Case Report
Neuromuscular and Clinical Neurophysiology (EMG)
P10 - Poster Session 10 (5:30 PM-6:30 PM)
1-006
To describe a case of adult-onset scapuloperoneal myopathy and cardiomyopathy with a novel myosin heavy chain 7 (MYH7) mutation. 

Myosin heavy chain 7 (MYH7)-related myopathies have variable clinical features and onsets and are emerging as a group of muscle diseases that affect a wide range of age groups. While individuals with (MYH7)-related myopathies will present with cardiac or skeletal involvement, it is less common to see cardiac and skeletal involvement occurring in a single individual. 

Case report+ PubMed was searched using keywords: “Scapuloperoneal myopathy,” and “MYH7 related myopathy.”
A 66-year old right-handed woman presented to the clinic for progressive ascending weakness, weight loss, and severe dysphagia. Symptoms first arose when the patient was in her 20s when she reported lower extremity weakness. Over the years, the weakness has ascended, and today the patient is unable to raise her arms. The patient has a family history of muscle disease, but testing has not been done. Neurological examination of mental status and cranial nerve were intact. Shoulder abduction, flexion, and extension was 2/5 bilaterally. Hip flexion was 3/5, and foot dorsiflexion was 2/5 bilaterally. There was no elevation of serum creatinine, and EMG showed myopathic process. Muscle biopsy of the deltoid revealed a myopathic changes with mini cores. EKG reveals first degree AV block with anterior ischemia and echocardiogram showing features of dilated cardiomyopathy. The genetic panel revealed c.4522_c.4524del (p.Glu1508del) resulting in pathogenic mutation of MYH7 leading to scapuloperoneal myopathy.

MYH7 gene-related myopathies have notable clinical variability that can lead to the missed or late diagnosis of this progressive myopathy. While our case highlights the pertinent family history and co-existing cardiac involvement that is strongly associated with MYH7 related myopathy, it also illustrates further cases of MYH7 mutations causing both cardiac and skeletal muscle disease.

Authors/Disclosures
Sara Hooshmand, MD (Mayo Clinic)
PRESENTER
Dr. Hooshmand has nothing to disclose.
Raghav Govindarajan, MD, FÂé¶¹´«Ã½Ó³»­ (HSHS St. Elizabeth Medical Group) Dr. Govindarajan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for MT pharma. Dr. Govindarajan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. Dr. Govindarajan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Argenx. Dr. Govindarajan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Catalyst. Dr. Govindarajan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche . Dr. Govindarajan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sarepta. Dr. Govindarajan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Amicus. Dr. Govindarajan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for UCB. Dr. Govindarajan has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Alexion. Dr. Govindarajan has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for MT pharma . Dr. Govindarajan has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Catalyst. Dr. Govindarajan has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Argenx. Dr. Govindarajan has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Biohaven. Dr. Govindarajan has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for UCB. Dr. Govindarajan has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Takeda. Dr. Govindarajan has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Abbvie. The institution of Dr. Govindarajan has received research support from Band of Hope . The institution of Dr. Govindarajan has received research support from Alexion. Dr. Govindarajan has received publishing royalties from a publication relating to health care.